|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small-cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Graves EE, Maity A and Le QT: The tumor
microenvironment in non-small-cell lung cancer. Semin Radiat Oncol.
20:156–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murakami A, Takahashi F, Nurwidya F,
Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K,
Shimada N, et al: Hypoxia increases gefitinib-resistant lung cancer
stem cells through the activation of insulin-like growth factor 1
receptor. PLoS One. 9:e864592014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mazumdar J, Dondeti V and Simon MC:
Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med.
13:4319–4328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iida H, Suzuki M, Goitsuka R and Ueno H:
Hypoxia induces CD133 expression in human lung cancer cells by
up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79.
2012.PubMed/NCBI
|
|
9
|
Ma I and Allan AL: The role of human
aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell
Rev. 7:292–306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Curtis SJ, Sinkevicius KW, Li D, Lau AN,
Roach RR, Zamponi R, Woolfenden AE, Kirsch DG, Wong KK and Kim CF:
Primary tumor genotype is an important determinant in
identification of lung cancer propagating cells. Cell Stem Cell.
7:127–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Freitas DP, Teixeira CA, Santos-Silva F,
Vasconcelos MH and Almeida GM: Therapy-induced enrichment of
putative lung cancer stem-like cells. Int J Cancer. 134:1270–1278.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizuno T, Suzuki N, Makino H, Furui T,
Morii E, Aoki H, Kunisada T, Yano M, Kuji S, Hirashima Y, et al:
Cancer stem-like cells of ovarian clear cell carcinoma are enriched
in the ALDH-high population associated with an accelerated
scavenging system in reactive oxygen species. Gynecol Oncol.
137:299–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brennan SK, Meade B, Wang Q, Merchant AA,
Kowalski J and Matsui W: Mantle cell lymphoma activation enhances
bortezomib sensitivity. Blood. 116:4185–4191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Terai H, Soejima K, Yasuda H, Nakayama S,
Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, et al:
Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism
of acquired resistance to gefitinib in NSCLC. Mol Cancer Res.
11:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ware KE, Hinz TK, Kleczko E, Singleton KR,
Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC
and Heasley LE: A mechanism of resistance to gefitinib mediated by
cellular reprogramming and the acquisition of an FGF2-FGFR1
autocrine growth loop. Oncogenesis. 2:e392013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGF-beta IL-6 axis mediates selective and adaptive
mechanisms of resistance to molecular targeted therapy in lung
cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang
YH, Wang YN, Li J and Gao FG: Interleukin 6 augments lung cancer
chemotherapeutic resistance via ataxia-telangiectasia
mutated/NF-kappaB pathway activation. Cancer Sci. 105:1220–1227.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu
HS and Hung SC: IL-6 enriched lung cancer stem-like cell population
by inhibition of cell cycle regulators via DNMT1 upregulation. Int
J Cancer. 136:547–559. 2015.PubMed/NCBI
|
|
20
|
Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim
NH, Amidon GL, Kim JS and Shin HC: Blockade of interleukin-6
receptor suppresses the proliferation of H460 lung cancer stem
cells. Int J Oncol. 41:310–316. 2012.PubMed/NCBI
|
|
21
|
Templeton AK, Miyamoto S, Babu A, Munshi A
and Ramesh R: Cancer stem cells: Progress and challenges in lung
cancer. Stem Cell Investig. 1:92014.PubMed/NCBI
|
|
22
|
Godin-Heymann N, Ulkus L, Brannigan BW,
McDermott U, Lamb J, Maheswaran S, Settleman J and Haber DA: The
T790M ‘gatekeeper’ mutation in EGFR mediates resistance to low
concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther.
7:874–879. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosell R, Karachaliou N, Morales-Espinosa
D, Costa C, Molina MA, Sansano I, Gasco A, Viteri S, Massuti B, Wei
J, et al: Adaptive resistance to targeted therapies in cancer.
Transl Lung Cancer Res. 2:152–159. 2013.PubMed/NCBI
|
|
25
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumar M, Allison DF, Baranova NN, Wamsley
JJ, Katz AJ, Bekiranov S, Jones DR and Mayo MW: NF-κB regulates
mesenchymal transition for the induction of non-small cell lung
cancer initiating cells. PLoS One. 8:e685972013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Min C, Eddy SF, Sherr DH and Sonenshein
GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J
Cell Biochem. 104:733–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akunuru S, James Zhai Q and Zheng Y:
Non-small cell lung cancer stem/progenitor cells are enriched in
multiple distinct phenotypic subpopulations and exhibit plasticity.
Cell Death Dis. 3:e3522012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC,
Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, et al: Inflammation
promotes expression of stemness-related properties in HBV-related
hepatocellular carcinoma. PLoS One. 11:e01498972016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Medema JP: Cancer stem cells: The
challenges ahead. Nat Cell Biol. 15:338–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin L, Hutzen B, Lee HF, Peng Z, Wang W,
Zhao C, Lin HJ, Sun D, Li PK, Li C, et al: Evaluation of STAT3
signaling in ALDH+ and ALDH+/CD44+/CD24− subpopulations of breast
cancer cells. PLoS One. 8:e828212013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shao C, Sullivan JP, Girard L, Augustyn A,
Yenerall P, Rodriguez-Canales J, Liu H, Behrens C, Shay JW, Wistuba
II and Minna JD: Essential role of aldehyde dehydrogenase 1A3 for
the maintenance of non-small cell lung cancer stem cells is
associated with the STAT3 pathway. Clin Cancer Res. 20:4154–4166.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van der Zee M, Sacchetti A, Cansoy M,
Joosten R, Teeuwssen M, Heijmans-Antonissen C, Ewing-Graham PC,
Burger CW, Blok LJ and Fodde R: IL6/JAK1/STAT3 signaling blockade
in endometrial cancer affects the ALDHhi/CD126+ stem-like component
and reduces tumor burden. Cancer Res. 75:3608–3622. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han Z, Wang X, Ma L, Chen L, Xiao M, Huang
L, Cao Y, Bai J, Ma D, Zhou J and Hong Z: Inhibition of STAT3
signaling targets both tumor-initiating and differentiated cell
populations in prostate cancer. Oncotarget. 5:8416–8428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab
T and Lin J: STAT3 signaling pathway is necessary for cell survival
and tumorsphere forming capacity in
ALDH+/CD133+ stem cell-like human colon
cancer cells. Biochem Biophys Res Commun. 416:246–251. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai
YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating
interleukin-6 level is a prognostic marker for survival in advanced
nonsmall cell lung cancer patients treated with chemotherapy. Int J
Cancer. 132:1977–1985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hennigan S and Kavanaugh A: Interleukin-6
inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk
Manag. 4:767–775. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sebba A: Tocilizumab: The first
interleukin-6-receptor inhibitor. Am J Health Syst Pharm.
65:1413–1418. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bayliss TJ, Smith JT, Schuster M, Dragnev
KH and Rigas JR: A humanized anti-IL-6 antibody (ALD518) in
non-small cell lung cancer. Expert Opin Biol Ther. 11:1663–1668.
2011. View Article : Google Scholar : PubMed/NCBI
|
